Thromb Haemost 2021; 121(07): 849-853
DOI: 10.1055/a-1477-3569
Invited Editorial Focus

Anticoagulant Treatment of COVID-19 as Early as Possible—Sulodexide and Perspectives

Sam Schulman
1  Department of Medicine, Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada
2  Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia
,
Job Harenberg
3  Heidelberg University, Heidelberg, Germany
4  DOASENSE GmbH, Heidelberg, Germany
› Author Affiliations

Sulodexide in the Treatment of Patients with Early Stages of COVID-19: A Randomized Controlled Trial

The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), infects endothelium, lung, heart, vascular system, gastrointestinal tube, kidney, and other organs via interaction of virus' spike S protein with angiotensin-converting enzyme 2 receptor on cell surfaces.[1] The infection mechanism includes proinflammatory changes in the arterial and venous walls resulting in endotheliitis followed by acute venous and arterial thrombosis contributing to up to 20% of COVID-19-related mortality.[2] However, patients may remain asymptomatic following infection or develop symptoms suspicious for COVID-19 approximately 5 days after infection with SARS-CoV-2.[3] Upon deterioration of symptoms, patients are hospitalized and anticoagulation with low-molecular weight heparin (LMWH) is now regarded as cornerstone therapy for admitted patients with COVID-19.[4] [5]

For asymptomatic patients with laboratory-confirmed COVID-19, it is uncertain whether hydroxychloroquine reduces hospitalization.[6] The National Institutes of Health treatment guidelines express uncertainty regarding the use of anti-SARS-CoV-2 monoclonal antibodies, bamlanivimab and casirivimab, in this population.[7] Fluvoxamine, otherwise used for compulsive obsessive disorder, exerts σ-1 receptor agonism with reduction of sepsis-related inflammatory response and was in a small randomized controlled trial (RCT) in nonhospitalized patients with COVID-19 associated with reduced clinical deterioration.[8] Convalescent plasma with high titers of SARS-CoV-2 antibodies reduced deterioration of respiratory symptoms in older outpatients with mild COVID-19 symptoms in a small RCT,[9] although a meta-analysis of four RCTs failed to demonstrate any benefit.[10]

Heparins and other glycosaminoglycans act on the thromboinflammatory process by their anticoagulant and nonanticoagulant effects.[11] Taking these potential new mechanisms of anticoagulants in consideration, the benefit of any glycosaminoglycan or anticoagulant of other origin may offer an attractive therapy for persons with mild or moderate symptoms of SARS-CoV-2 to prevent hospitalization.

Several studies are in progress to investigate the benefit of an anticoagulant given as early as possible for patients suffering from mild to moderate severity of COVID-19 using LMWH, sulodexide, the direct oral anticoagulants (DOACs) apixaban and edoxaban, and the antiplatelet drug acetylsalicylic acid (ASA) at various doses. Some studies add colchicine to ensure an anti-inflammatory action of DOACs or ASA ([Table 1]).[12] [13] [14] [15] [16] [17] [18] [19] The unmet clinical need is speeding up planning of studies and therefore, some of the planned or ongoing trials may be missing in this listing.

Table 1

Clinical studies on treatment of COVID-19 at home. Search results in https://clinicaltrials.gov with keywords: COVID-19, anticoagulation, as of 18 March 2021:

Trial ID (ref.)

Anticoagulant control

Dose duration

Primary outcome

Participants

(N)

Design

Estimated study end-date

NCT04400799[12]

Enoxaparin

control

40 mg od

No study drugs

14 days

Hospitalization

all-cause mortality

day 14

1,000

Prospective, open label

randomized

multicentric

April 2021

NCT04508439[13]

Enoxaparin

enoxaparin

40 mg od and

1 mg/kg bw bid sc

15 days crossover

30 days total

Hospital care admission

days in hospital care,

days supplemental oxygen

day 30

130

Prospective, randomized open label, crossover assignment, monocentric

December 2020

NCT04483830[15]

Sulodexide

placebo

500 LRU bid

placebo pills

21 days

Hospital care admission, days in

hospital care, days supplemental

oxygen, day 21

D-dimer and CRP, days 0 vs. 14

243

Prospective

randomized

placebo-controlled,

multicentric

September 2020

NCT04746339[16]

Apixaban

placebo

2.5 mg bid

Placebo pills

Days alive and out of hospital

day 30

1,000

Prospective, randomized, quadruple blind, multicentric

December 2021

NCT04498273[17]

Apixaban

aspirin

placebo

2.5 mg bid

5 mg bid

81 mg od

No treatment

30 days

Composite endpoint:

hospitalization for cardiovascular/pulmonary events, symptomatic VTE, arterial thromboembolism, myocardial infarction, ischemic stroke, all-cause mortality

day 45

7,000

Prospective

randomized

quadrupleblind,

multicentric

September 2021

NCT04516941[18]

Edoxaban

colchicine

control

60 mg od

30 mg od if CrCl ≤ 50 mL/min or BW ≤ 60 kg

25 ± 3 days

0.5 mg bid, 3 days

0.5 mg od day 4 to 14 ± 3 or 25 ± 3

No active treatment

Edoxaban vs. control: asymptomatic proximal DVT, symptomatic PE and DVT, myocardial infarction, ischemic stroke, non-CNS systemic embolism, mortality, day 25 ± 3

Colchicine vs. control: SARS-CoV-2 clearance rates determined by PCR or freedom from death or hospitalization, day 14 ± 3

420

Prospective

randomized

open label

22 factorial design

bicentric

December 2021

NCT04324463[19]

Colchicine

aspirin

control

rivaroxaban

interferon-beta

0.6 mg bid 3 days

0.6 mg od day 4 to 25

75–100 mg od

Usual care 25 days

2.5 mg bid, inpatients only Inpatients only

Colchicine–aspirin:

composite of hospitalization or death

day 45

4,000

Prospective

open-label

parallel group

22 factorial design

randomized

multicentric

June 2021

NCT04518735[24]

Chronic therapy

warfarin, acenocumarol

dabigatran, apixaban, edoxaban

rivaroxaban

aspirin, clopidogrel, prasugrel, ticagrelor, cangrelor, dipyridamole no anticoagulant therapy

According approved treatment regimens, any indication

VKA and antiplatelet therapy and control: comparison of clinical outcomes depending on previous antithrombotic therapy per group, mortality, transfer to the intensive care unit, day 28

1,707

Retrospective

case–control

monocentric

June 2020

Abbreviations: bid, twice a day; BW, body weight; CNS, central nervous system; DVT, deep vein thrombosis; od, once daily; PCR, polymerase chain reaction; PE, pulmonary embolism; sc, subcutaneous; VKA, vitamin K antagonist; VTE, venous thromboembolism.


The first trial is now published by Gonzalez Ochoa et al evaluating sulodexide for individuals with early stages of COVID-19 to reduce the proportion of hospitalized patients and their length of hospital stays, the proportion of patients requiring oxygen support, and the number of days on such support.[15] [20] They took advantage of the lack of an approved anticoagulant therapy to design a trial with the orally available glycosaminoglycan sulodexide versus placebo with blinding of study personal and participants. The low risk of bleeding during treatment with sulodexide may have increased the confidence in this treatment. A recent meta-analysis has shown that sulodexide was associated with reduced odds of all-cause mortality, cardiovascular mortality, myocardial infarction, and deep vein thrombosis, without a significant increase in bleeding compared with placebo or no treatment.[21]

Gonzalez Ochoa et al followed the standard procedures with permuted block randomization at a 1:1 ratio of capsules containing 500 lipid releasing units sulodexide or placebo given twice daily for 21 days. They included patients aged >40 years with suspicion of COVID-19 and with at least 3 days with two of the symptoms: cough, fever, or headache, plus one of runny nose, diarrhea, dyspnea, loss of taste or smell, conjunctivitis, and body or muscle ache. A polymerase chain reaction (PCR) test for SARS-CoV-2 had to be presented by participants within 3 days of randomization and if negative, medication was stopped and patients were observed until end of study for intention-to-treat (ITT) analysis. Follow-up of participants was done virtually or in person for 21 days and further until an outcome had occurred or until the end of the trial. The primary endpoint of hospitalization occurred statistically significantly less frequently in participants on sulodexide (17.4%) versus placebo (29.4%) (p = 0.031). Secondary endpoints showed significantly less frequent and shorter requirement of oxygen support at home plus in-hospital for participants on sulodexide compared with placebo. Length of hospital stay, mortality, and hemorrhage were not different between the groups. All results were confirmed by the ITT analysis.

The concentrations of D-dimer and C-reactive protein (CRP) were normal and not different between participants treated with sulodexide and placebo at baseline. At day 14, D-dimer and CRP were higher in both groups compared with baseline, but were significantly higher during administration of placebo compared with sulodexide. This finding is of particular interest for the pathophysiology of COVID-19 and the anticoagulant and anti-inflammatory properties of sulodexide and potential usefulness for identification of patients who may suffer from a progression of COVID-19 when treated at home.

Strengths and limitations of the study were considered by the authors and some may be worth to be added.

Strengths of the study:

  • Not to wait for the results of the PCR result for SARS-CoV-2 to start the study drug.

  • To use the higher of the available doses of sulodexide for the participants.

  • To determine D-dimer and CRP at start and after 14 days to generate information on the potential benefit of the anticoagulant and anti-inflammatory actions of sulodexide for home treatment.

Limitations may be added, such as:

  • The relatively small sample size and that 12% could not be analyzed due to lack of data.

  • The lack of dose adjustment or change to LMWH or a DOAC in participants with increase of D-dimer at day 14.

  • The lack of analysis according to elevation of D-dimer and/or CRP at day 14 per group.



Publication History

Received: 21 March 2021

Accepted: 06 April 2021

Publication Date:
08 April 2021 (online)

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany